TNFRSF8 and Hodgkins lymphoma: In the case of HL, EV/Exo express higher levels of CD30 than other membrane receptors, therefore circulating CD30 in EV/Exo received special attention due to the relevance of CD30 in HL diagnosis and the effectiveness of anti-CD30 mAb brentuximab-vedotin in HL therapy [88,91,94,95].